SINGAPORE (Reuters) – AstraZeneca said on Friday it will supply Singapore with its COVID-19 antibody cocktail, Evusheld, by the end of the year.
Evusheld can act as another layer of protection, alongside vaccines, for people who are at high risk of COVID-19 infection, according to AstraZeneca’s statement.
The company did not specify how many courses of the treatment would be supplied to the Southeast Asian city-state.
The U.S. Food and Drug Administration on Wednesday authorised the use of Evusheld to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines.
(Reporting by Chen Lin in Singapore; Editing by Ed Davies)
Wanda Rich has been the Editor-in-Chief of Global Banking & Finance Review since 2011, playing a pivotal role in shaping the publication’s content and direction. Under her leadership, the magazine has expanded its global reach and established itself as a trusted source of information and analysis across various financial sectors. She is known for conducting exclusive interviews with industry leaders and oversees the Global Banking & Finance Awards, which recognize innovation and leadership in finance. In addition to Global Banking & Finance Review, Wanda also serves as editor for numerous other platforms, including Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune.